Bibiana Bielekova

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Development of biomarkers in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    Brain 127:1463-78. 2004
  2. ncbi request reprint Antigen-specific immunomodulation via altered peptide ligands
    B Bielekova
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Building 10, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    J Mol Med (Berl) 79:552-65. 2001
  3. ncbi request reprint MRI as a marker for disease heterogeneity in multiple sclerosis
    B Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892 1400, USA
    Neurology 65:1071-6. 2005
  4. pmc Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C103, 10 Center Dr, MSC 1400, Bethesda, MD 20892, USA
    Arch Neurol 66:483-9. 2009
  5. pmc Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Mult Scler 15:1206-14. 2009
  6. pmc An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
    Jayne F Martin
    Neuroimmunology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:1311-20. 2010
  7. pmc Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases
    Sungpil Han
    Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892
    J Immunol 192:2551-63. 2014
  8. pmc Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
  9. pmc CNS vasculitis in a patient with MS on daclizumab monotherapy
    Joan Ohayon
    Neuroimmunology Branch, National Institutes of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, MD, USA
    Neurology 80:453-7. 2013
  10. pmc Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis
    Justin S A Perry
    Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 4:145ra106. 2012

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Development of biomarkers in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg 10, Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    Brain 127:1463-78. 2004
    ..This review summarizes the general concepts of biomarkers and their potential use as surrogate endpoints and tailors these concepts to specific applications in multiple sclerosis research...
  2. ncbi request reprint Antigen-specific immunomodulation via altered peptide ligands
    B Bielekova
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Building 10, 10 Center DR MSC 1400, Bethesda, MD 20892 1400, USA
    J Mol Med (Berl) 79:552-65. 2001
    ..We summarize current knowledge of the basic mechanisms of the effects of APLs with special focus on T cell receptor signaling and the use of APLs for the treatment of autoimmune diseases...
  3. ncbi request reprint MRI as a marker for disease heterogeneity in multiple sclerosis
    B Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD 20892 1400, USA
    Neurology 65:1071-6. 2005
    ....
  4. pmc Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C103, 10 Center Dr, MSC 1400, Bethesda, MD 20892, USA
    Arch Neurol 66:483-9. 2009
    ..Several questions arise concerning the use of the anti-CD25 antibody daclizumab to treat multiple sclerosis (MS)...
  5. pmc Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Mult Scler 15:1206-14. 2009
    ..We conclude that the reasons underlying the discrepancy between the therapeutic efficacy of rolipram in experimental autoimmune encephalomyelitis versus multiple sclerosis are at present not clear...
  6. pmc An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells
    Jayne F Martin
    Neuroimmunology Branch, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:1311-20. 2010
    ..Our study provides insight into the role that IL-2 and CD25 play in functional regulation of two important immunoregulatory cell populations in humans: FoxP3(+) Tregs and CD56(bright) NK cells...
  7. pmc Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuroimmunological diseases
    Sungpil Han
    Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892
    J Immunol 192:2551-63. 2014
    ....
  8. pmc Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:5941-6. 2006
    ..This immunoregulation has potential importance for the treatment of autoimmune diseases and transplant rejection and toward modification of tumor immunity...
  9. pmc CNS vasculitis in a patient with MS on daclizumab monotherapy
    Joan Ohayon
    Neuroimmunology Branch, National Institutes of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, MD, USA
    Neurology 80:453-7. 2013
    ..To report the development of CNS vasculitis in a patient with multiple sclerosis (MS) treated with daclizumab...
  10. pmc Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis
    Justin S A Perry
    Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 4:145ra106. 2012
    ..Our study indicates that ILCs are involved in the regulation of adaptive immune responses, and their role in human autoimmunity should be investigated further, including their potential as therapeutic targets...
  11. pmc A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
    Simone C Wuest
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, Maryland, USA
    Nat Med 17:604-9. 2011
    ..Our data reveal a previously unknown mechanism for the IL-2 receptor system in DC-mediated activation of T cells...
  12. pmc Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
    Yen Chih Lin
    Neuroimmunological Diseases Unit, Neuroimmunology Branch Y C L, P W, A B, E R, B B and Clinical Neuroscience Program T W, National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD FDA J M, L R K, H G, CBER and NIH Center for Human Immunology B B, NIH, Bethesda, MD
    Neurol Neuroimmunol Neuroinflamm 3:e196. 2016
    ....
  13. pmc Novel composite MRI scale correlates highly with disability in multiple sclerosis patients
    Peter Kosa
    Neuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA Electronic address
    Mult Scler Relat Disord 4:526-35. 2015
    ..As such, it represents a broadly available clinical and research tool that can facilitate multicenter research studies and comparative analyses across patient cohorts and research projects...
  14. pmc A complex role of herpes viruses in the disease process of multiple sclerosis
    Simone C Wuest
    Neuroimmunological Diseases Unit, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 9:e105434. 2014
    ..The data suggest that intrathecal administration of novel therapeutic agents targeting immune cells outside of the proliferation cycle may be necessary to effectively eliminate intrathecal inflammation in progressive MS. ..
  15. pmc Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    PLoS ONE 7:e48370. 2012
    ....
  16. ncbi request reprint Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:3893-904. 2004
    ..These data have important implications for autoimmunity research and should be considered in the development of Ag-specific therapies in MS...
  17. pmc Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis
    Wenzheng Jiang
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 187:781-90. 2011
    ..Our study describes the important physiological role that GrK plays in immunoregulation of adaptive immunity in humans and indicates that therapeutic exploitation of this pathway is beneficial in controlling autoimmunity...
  18. doi request reprint Monoclonal antibodies in MS: mechanisms of action
    Bibiana Bielekova
    Neuroimmunological Diseases Unit, National Institute NIH, Bethesda, MD 20892, USA
    Neurology 74:S31-40. 2010
    ....
  19. pmc Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment
    Peter Kosa
    Neuroimmunological Diseases Unit, National Institute of Neurological Diseases and Stroke, National Institute of Health, Bethesda, MD, USA
    Front Neurol 7:131. 2016
    ....
  20. pmc Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis
    Jiwon Oh
    From the Department of Neurology J Oh, S S, P A C, S D N, Johns Hopkins University, Baltimore and Neuroimmunology Branch I C, J Ohayon, B B, National Institute of Neurological Disorders and Stroke, Bethesda, MD
    Neurology 82:984-8. 2014
    ..To report 3 patients with multiple sclerosis (MS) who presented with daclizumab-related adverse events (AEs) in multiple organ systems...
  21. pmc Daclizumab therapy for multiple sclerosis
    Bibiana Bielekova
    Neuroimmunological Diseases Unit NDU, Neuroimmunology Branch NIB, National Institute of Neurological Disorders and Stroke NINDS, Bethesda, MD 20892, USA
    Neurotherapeutics 10:55-67. 2013
    ....
  22. ncbi request reprint Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease
    Roberto Bomprezzi
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bldg 50 Room 5150, Bethesda, MD 20892 8000, USA
    Hum Mol Genet 12:2191-9. 2003
    ....
  23. doi request reprint National Institutes of Health Center for Human Immunology Conference, September 2009
    Robert B Nussenblatt
    Laboratory of Immunology, National Eye Institute, Maryland 20892, USA
    Ann N Y Acad Sci 1200:E1-23. 2010
    ..The human immunology meeting was held in the Clinical Center of the National Institutes of Health, Bethesda, Maryland, on September 3 and 4, 2009...
  24. ncbi request reprint Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease
    R Martin
    Neuroimmunology Branch, NINDS, NIH Building, 10 Room 5B 16, 10 Center DR MSC 1400, Bethesda, MD, 20892 1400, USA
    J Autoimmun 16:187-92. 2001
    ..Thus, we provide firm evidence that the basic principles of cross-recognition and their pathogenetic significance are relevant in MS...
  25. pmc The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis
    Isabela T Borges
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA
    Mult Scler Relat Disord 2:133-140. 2013
    ..In summary, in this retrospective analysis, daclizumab therapy substantially decreased the rate of brain atrophy in relapsing-remitting MS in comparison to other disease-modifying therapies, predominantly interferon β...
  26. pmc Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
    Irene Cortese
    From the Neuroimmunology Clinic I C, J O and the Neuroimmunological Diseases Unit B B, National Institute of Neurological Disorders and Stroke, and the Laboratory of Pathology C C L, M R and the Dermatology Branch E W C, J J D, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda and Department of Neurology K F, Johns Hopkins School of Medicine, Baltimore, MD
    Neurology 86:847-55. 2016
    ..To analyze the spectrum and mechanisms of cutaneous adverse events (AEs) in patients with multiple sclerosis treated with daclizumab high-yield process (DAC-HYP)...
  27. doi request reprint Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis
    Mika Komori
    Neuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD
    Ann Neurol 78:3-20. 2015
    ....
  28. pmc Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders
    Paolo A Muraro
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, MD 20892 1400, USA
    Brain 126:20-31. 2003
    ....
  29. pmc Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination
    Muktha S Natrajan
    1 Wellcome Trust MRC Cambridge Stem Cell Institute, and Department of Clinical Neurosciences, University of Cambridge, Cambridge, CB2 0AH, UK 2 Neuroimmunological Diseases Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
    Brain 138:3581-97. 2015
    ..These results reveal the retinoid X receptor pathway as a positive regulator of myelin debris clearance and a key player in the age-related decline in remyelination that may be targeted by available or newly-developed therapeutics...
  30. pmc Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta
    Bibiana Bielekova
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:8705-8. 2004
    ..Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures...
  31. ncbi request reprint VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis
    P A Muraro
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive MSC1400, 20892 1400, Bethesda, MD, USA
    J Neuroimmunol 111:186-94. 2000
    ..These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS...
  32. ncbi request reprint Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes
    K P Wandinger
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA
    Ann Neurol 50:349-57. 2001
    ....
  33. ncbi request reprint Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b
    S Markovic-Plese
    Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD 20892 1400, USA
    Neurology 60:1849-51. 2003
    ..A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002)...
  34. pmc Biomarkers in multiple sclerosis
    Roland Martin
    Catalan Institute for Research and Advanced Studies and Unidad de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Dis Markers 22:183-5. 2006
  35. ncbi request reprint Emerging therapies for multiple sclerosis
    Paolo A Muraro
    Department of Cellular and Molecular Neuroscience, Imperial College London, London SW7 2AZ, United Kingdom
    Neurotherapeutics 4:676-92. 2007
    ..The evidence supporting the potential of these emerging immunotherapies suggests that strong progress is being made in the development of effective cures for multiple sclerosis...